Spectra254, a developer of high-power, easy-to-use, affordable UV-C light decontamination systems, announced that results from an independent laboratory study finds Spectra254’s 1000 Series ultraviolet light system to be 99.9 percent effective in killing an Ebola surrogate virus.
The study, conducted by Antimicrobial Test Laboratories, found the ultraviolet light system is 99.9 percent effective at killing the Ebola surrogate on surfaces at a distance of up to 10 feet. These results are significant given the Ebola virus’ recent infection rates worldwide.
The laboratory measured efficacy at distances of five, 10 and 15 feet, both vertically and horizontally. The study tested the microorganism Feline calicivirus (FCV), the closest to the real virus that can legally be tested. Feline calicivirus also meets the CDC Ebola Disinfection Guidelines for Selection of Appropriate Test Virus.
“The independent lab finding proving the effectiveness of Spectra254 system eliminating Ebola is substantial,” says Sanford Green, president of Spectra254. “Ebola is a virus that has ravaged West Africa and has the world on edge. Healthcare professionals need proven tools and equipment that can reliably eliminate this virus on surfaces.”
The Spectra 1000 Series UVC light decontamination systems use high-intensity UVC light to eliminate pathogens on surfaces. The company’s devices are currently in use at hospitals throughout North America, as well as ambulatory care, medical clinics and education facilities.
Source: Spectra254
The Role of Environmental Hygiene in Preventing Antimicrobial Resistance
March 19th 2024Uncover the pivotal role of environmental hygiene in thwarting antimicrobial resistance (AMR) for infection prevention teams. Learn how rigorous cleaning protocols and advanced technologies enhance patient safety and combat AMR.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.